KGKarl De Geer

Karl De Geer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karl De Geer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Erik Björck

    Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

    5 shared publications
  • Anna Lindstrand

    Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

    3 shared publications
  • Eliane Sardh

    Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

    2 shared publications
  • Karin Naess

    Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • Katarzyna Mascianica

    Vitreoretinal Department, St. Erik Eye Hospital, Stockholm, Sweden

    2 shared publications
  • Björn Hammar

    Department of Clinical Sciences Lund, Ophthalmology, Lund University, Skane University Hospital, Lund, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Biallelic PAX6 Variants in an Adult With Severe Microphthalmia and Preserved Intellectual Function

    by Karl De Geer, Britt‐Marie Anderlid, Lena Jacobson, Daniel Martín Muñoz, Erik Björck

    PAX6 encodes a dosage‐sensitive transcription factor that is essential for eye development. Heterozygous PAX6 disease is well characterized, but biallelic disease is extremely rare and has been associated with anophthalmia, severe brain malformations, and perinatal lethality. Here we report the first adult patient with biallelic pathogenic PAX6 variants and describe a novel phenotype that includes severe microphthalmia, anosmia, and autism spectrum disorder, Level 1. Notably, intellectual function was preserved. Genome sequencing revealed compound heterozygosity for the missense variant c.622C>T p.(Arg208Trp), inherited from the patient's mother diagnosed with sclerocornea and iris hypoplasia, and the nonsense variant c.718C>T p.(Arg240*), inherited from the patient's father diagnosed with aniridia. We compare the phenotype and genotype with previously reported biallelic patients and observe that the neurological phenotype of the patient fits the pattern observed in PAX6 haploinsufficiency. We propose that the severe microphthalmia is the result of haploinsufficiency and a hypomorphic, eye‐restricted effect of the missense variant, which is predicted to affect the DNA‐binding homeodomain of PAX6 . Together, these findings expand the phenotypic spectrum of biallelic PAX6 disease and suggest that the homeodomain may have a tissue‐specific role that is critical for eye development but largely dispensable for brain development.

  • Open Access

    Dystrophia Smolandiensis is characterized by a novel NQO1 variant and a distinct phenotype from COL17A1 ‐associated epithelial recurrent erosion dystrophy

    by Karl De Geer, Kristina Lagerstedt‐Robinson, Daniel Nilsson, Cilla Söderhäll, Björn Hammar, Erik Björck

    Purpose: To determine the molecular cause of the two epithelial recurrent erosion dystrophies, Dystrophia Smolandiensis and Dystrophia Helsinglandica, and to identify phenotypic differences between the two conditions. Methods: DNA samples and clinical data from structured interview records were obtained from the Swedish families in which Dystrophia Smolandiensis and Dystrophia Helsinglandica were originally characterized. Candidate variant detection was performed using combinations of linkage analysis, Sanger sequencing, exome sequencing and genome sequencing. Differences in age of onset and precipitating factors of erosive episodes were assessed using the Wilcoxon rank sum test and Fisher's exact test. Results: In Dystrophia Smolandiensis, the novel candidate variant NQO1 c.535 T>A p.(Phe179Ile) co‐segregated with disease across 49 informative meioses. In Dystrophia Helsinglandica, the known pathogenic splice variant COL17A1 c.3156C>T was identified. There were significant phenotypic differences between the two conditions. The median age of onset was lower in Dystrophia Smolandiensis (2.5 years vs. 6 years, p = 0.00065). Cigarette smoke, intense sunlight and pregnancy were distinct precipitating factors of erosive episodes in Dystrophia Smolandiensis ( p = 0.0010, p < 0.0001 and p = 0.016, respectively), whereas minor trauma to the eye was specific to Dystrophia Helsinglandica ( p < 0.0001). Conclusion: NQO1 is a candidate gene for Dystrophia Smolandiensis, while Dystrophia Helsinglandica is synonymous with COL17A1 ‐associated ERED. The two conditions are characterized by distinct phenotypic differences. Based on these findings, we suggest a reclassification of epithelial recurrent erosion dystrophies guided by genetics. We propose designating COL17A1 ‐associated epithelial recurrent erosion dystrophy as ERED1 and NQO1 ‐associated epithelial recurrent erosion dystrophy as ERED2.

  • Open Access

    The value of age of onset and family history as predictors of molecular diagnosis in a Swedish cohort of inherited retinal disease

    by Karl De Geer, Stefan Löfgren, Anna Lindstrand, Malin Kvarnung, Erik Björck

    Purpose: This study aimed to characterize clinical and genetic findings in a Swedish cohort with inherited retinal disease (IRD), identify predictors for achieving a molecular diagnosis and evaluate the effects of increased genetic testing over time.Methods: Clinical and genetic data from 324 nonrelated IRD index individuals referred for genetic testing in the Stockholm region between 2016 and 2023 were collected retrospectively and analysed by clinical subtype, age of onset and testing period (2016–2020 vs. 2021–2023). Logistic regression was used to calculate odds ratios for age of onset and family history on the likelihood of achieving a molecular diagnosis.Results: The diagnostic yield was 55% and involved 56 genes. In 10% of solved individuals, the molecular diagnosis refined the clinical diagnosis. For each 1‐year increase in age of onset, the odds of achieving a molecular diagnosis decreased by 3% (odds ratio 0.97, 95% confidence interval 0.96–0.98). A positive family history doubled the odds (odds ratio 2.1, 95% confidence interval 1.3–3.4). The use of genetic testing increased 2.1‐fold and the number of molecular diagnoses increased 1.6‐fold relative to the population of the Stockholm region between the two testing periods.Conclusion: This study adds to the knowledge of the clinical and genetic landscape of IRDs in Sweden and establishes age of onset and family history as significant predictors for achieving a molecular diagnosis. Increased genetic testing on a population level substantially increased the number of individuals receiving a molecular diagnosis with a high diagnostic yield compared to other rare diseases.


  • Open Access

    Unraveling mucolipidosis type III gamma through whole genome sequencing in late-onset retinitis pigmentosa: a case report

    by Karl De Geer, Katarzyna Mascianica, Karin Naess, Eliane Sardh, Anna Lindstrand, Erik Björck

    Background: We describe the case of a 47-year-old man referred to a retinal clinic and diagnosed with late-onset retinitis pigmentosa. Surprisingly, genetic testing revealed compound heterozygous pathogenic variants in GNPTG, leading to the diagnosis of the autosomal recessive lysosomal storage disorder mucolipidosis type III gamma. Mucolipidosis type III gamma is typically diagnosed during childhood due to symptoms relating to skeletal dysplasia. Retinal dystrophy is not a common phenotypic feature. Case presentation: Ophthalmologic examination was consistent with a mild form of retinitis pigmentosa and included fundus photography, measurement of best-corrected visual acuity, optical coherence tomography, electroretinogram and visual field testing. Extraocular findings included joint restriction and pains from an early age leading to bilateral hip replacement by age 30, aortic insufficiency, and hypertension. Genetic analysis was performed by whole genome sequencing filtered for a gene panel of 325 genes associated with retinal disease. Two compound heterozygous pathogenic variants were identified in GNPTG, c.347_349del and c.607dup. The diagnosis of mucolipidosis type III gamma was confirmed biochemically by measurement of increased activities of specific lysosomal enzymes in plasma. Conclusion: To our knowledge this is the first description of retinitis pigmentosa caused by compound heterozygous variants in GNPTG, providing further indications that late-onset retinal dystrophy is part of the phenotypic spectrum of mucolipidosis type III gamma.


  • Open Access

    Unraveling mucolipidosis type III gamma through whole genome sequencing in late-onset retinitis pigmentosa: a case report

    by Karl De Geer, Katarzyna Mascianica, Karin Naess, Eliane Sardh, Anna Lindstrand, Erik Björck

    Background: We describe the case of a 47-year-old man referred to a retinal clinic and diagnosed with late-onset retinitis pigmentosa. Surprisingly, genetic testing revealed compound heterozygous pathogenic variants in GNPTG, leading to the diagnosis of the autosomal recessive lysosomal storage disorder mucolipidosis type III gamma. Mucolipidosis type III gamma is typically diagnosed during childhood due to symptoms relating to skeletal dysplasia. Retinal dystrophy is not a common phenotypic feature. Case presentation: Ophthalmologic examination was consistent with a mild form of retinitis pigmentosa and included fundus photography, measurement of best-corrected visual acuity, optical coherence tomography, electroretinogram and visual field testing. Extraocular findings included joint restriction and pains from an early age leading to bilateral hip replacement by age 30, aortic insufficiency, and hypertension. Genetic analysis was performed by whole genome sequencing filtered for a gene panel of 325 genes associated with retinal disease. Two compound heterozygous pathogenic variants were identified in GNPTG, c.347_349del and c.607dup. The diagnosis of mucolipidosis type III gamma was confirmed biochemically by measurement of increased activities of specific lysosomal enzymes in plasma. Conclusion: To our knowledge this is the first description of retinitis pigmentosa caused by compound heterozygous variants in GNPTG, providing further indications that late-onset retinal dystrophy is part of the phenotypic spectrum of mucolipidosis type III gamma.